BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and ...

FILE - In this June 15, 2005, file photo, a sign stands in front of a Bristol-Myers Squibb building in a Lawrence Township, N.J. Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. During ...

Karuna Therapeutics KRTX signed a definitive merger agreement with Bristol Myers Squibb BMY. Per the agreement terms, Bristol Myers will acquire all outstanding shares of Karuna for $330 per share in ...

Fintel reports that on July 13, 2023, William Blair maintained coverage of Karuna Therapeutics (NASDAQ:KRTX) with a Outperform recommendation. As of July 6, 2023, the average one-year price target for ...

Drugmaker Bristol Myers BMY0.90%increase; green up pointing triangle Squibb reached a deal to buy neuroscience-drug developer Karuna Therapeutics for $14 billion. Under the terms, Bristol would pay ...

Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimer’s drugmaker Karuna Therapeutics for $14 billion. Bristol Myers said it would pay $330 a share cash for ...

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even ...

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and ...

Karuna's stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%. The deal will help expand Bristol Myers' drug pipeline after competition ...